X-In8 Biologicals Corporation
Business Identifier: therapies to fight inflammation and other tissue damage
Public Profile:
Biotechnology company X-in8 Biologicals Corp., a spinoff from the laboratories at the University of North Carolina at Chapel Hill. X-in8 is developing therapies that can fight inflammation and other tissue damage as blood flow is restored after the blood supply has been restricted for a period of time, such as after an organ transplant. The damage that can occur is called ischemia-reperfusion injury, or IRI. Prncipals of the firm are working on a way to keep naturally occurring proteins from contributing to IRI. Egan said the compounds he is developing could reduce tissue damage after transplants. The technology could also be developed for heart surgery as well as heart attack and stroke applications.

 Synopsis: Awardee Business Condition
Year Founded IP Holdings
Employee Range VC funded?
Revenue Range Private/Public
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
Tlr4 Inhibition To Reduce Cerebral Ischemia Reperfusion Injury
The Effect Of Tlr4 Inhibition On Lung Transplant Ischemia-Reperfusion Injury